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ABSTRACT 
 
Background: 
Although health-related Quality of life (HRQOL) has become an important outcome measure 
in surgical trials, questions still remain about the quality of its reporting. 
The aim of this study was to evaluate HRQOL assessment methodology of randomized 
clinical trials concerning gastrointestinal surgery. 
 
Methods: 
All articles published in the calendar years 2006 and 2007 that purported to assess quality of 
life as end points or make some conclusion about quality of life were chosen for review from 
eight general surgical journals and four medical journals. Identified eligible studies were 
selected and then evaluated on a broad set of predetermined criteria. 
 
Results: 
Twenty-four published RCTs with an HRQOL component were identified. Although most 
trials exhibited good-quality research , some methodological limitations were identified: only 
21% of the studies gave a rationale for selecting a specific HRQOL measure, 46% of the 
studies failed to report information about the administration of the HRQOL measure, and 37% 
did not give details on missing data. 
 
Conclusions: 
Although it is clear that HRQOL is an important end point in surgical RCTs because the 
information helps to influence treatment recommendations,a number of methodological 
shortcomings have to be further addressed in future studies. 
 
Key words: quality of life, randomized controlled trial, surgery 
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INTRODUCTION 
 
This century we have witnessed significant progress in the diagnosis and treatment of disease. 
The effects of disease and its treatment on patients have traditionally been assessed in terms 
of pain scores, duration of hospital stay, and return to normal activities. These outcomes, 
however, are dependent much on external factors, such as on local habits and social security 
matters. Thus, the application of quality-of-life instruments, which measure recovery in a 
patient-centered manner, has become more popular in recent times and has been accepted 
more and more as a solid primary outcome measure in scientific studies [1]. 
 
At the present time, there is no single definition of HRQOL. Nevertheless, there is a broad 
consensus that it refers to the physical, psychologic, and social functioning of patients and the 
impact of disease and treatment on their abilities and daily functioning [2-5]. 
 
There are several valid measures of HRQOL that are suitable to use in surgical research. 
Generic measures (such as the short form health survey SF-36 [6]) broadly assess physical, 
mental, and social health and can be used to compare conditions and treatments. Measures 
specific to illnesses (such as the Gastro-Intestinal Quality of Life Index GIQLI[7]) can 
supplement generic measures or can be used independently [8]. 
 
Although these instruments are widely available, careful application of the tools in clinical 
studies is needed to produce reliable and clinically useful results. These range from the 
accurate selection of the most appropriate instrument for the particular trial objective, to the 
handling of missing data and accurate interpretation of outcomes [9-11]. Unless standards for 
measuring HRQOL are adhered to in clinical trials, the data that are collected will be difficult 
to interpret and unlikely to make clinical sense [11]. 
 
Previous review on randomised controlled clinical trials (RCTs) including an HRQOL 
evaluation in oncology have shown overall a number of methodological shortcomings [12-
19]. 
However, to date, no detailed systematic methodological review of the quality of the conduct 
and reporting of QOL results from RCTs for gastrointestinal surgery has appeared. Therefore, 
the aim of this study was to evaluate the quality of HRQOL methodologic assessment in 
randomized controlled clinical trials (RCTs) involving the gastrointestinal surgery, and 
determine how improvements can be made. 
 
Because they are considered the optimal study design for evaluating the effects of different 
surgical interventions [20], we limited our search to « randomized controlled trials » and to 
recent articles published between January 2006 and December 2007. 
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METHODS 
 
Search strategy for identification of studies 
Twelve journals were chosen for review : eight English-language surgical journals (American 
Journal of Surgery, Annals of Surgery, Archives of Surgery, Journal of the American College 
of Surgeons, Surgery; British Journal of Surgery, European Journal of Surgical Oncology) 
and four English-language medical journals (New England Journal of Medicine, Lancet, 
British Medical Journal, and Journal of the American Medical Association).  
 
To identify eligible articles, all issues of these journals were hand-searched. 
 
Studies included for review had to be randomised-controlled gastro-intestinal surgical trials, 
phases III published between 01/01/2006 and 31/12/2007. 
 
All randomised-controlled trials (RCTs) comparing different treatment were eligible, 
regardless of the intervention type. No restrictions were performed on trial location, number 
of patients enrolled in the trial, treatment modalities and sponsor of trial. 
 
The exclusion criteria were: (a) trials published as a letter, abstract, or short article; (b) 
randomised phase II trials; and (c) non-experimental (observational) studies. 
 
The search was restricted to RCTs as they represent the gold standard by which health care 
professionals make decisions about treatment effectiveness [20]. 
 
Characteristics assessed 
Two reviewers (V.B. and JJ.T.), who were not involved in any of the identified studies, 
analysed the identified RCTs independently. Any disagreement was resolved through 
discussion between the two reviewers. 
 
As Quality of Life (QOL) was the main outcome measure sought, any studies including 
assessing quality of life as an end point or making some conclusion about quality of life were 
considered. 
 
The standardised protocol was based on a checklist (available from the authors). The items to 
be included were: country of origin, industry funded (yes versus no), number of patients 
randomised, multicenter studies (yes versus no), informed consent reported (yes versus no), 
approval of a research ethics committee reported (yes versus no) and Health Related Quality 
of Life (HRQOL) difference between treatment arms (yes versus no). The latter was defined 
as any statistical difference between treatment arms at any given time point assessment during 
the trial (even if this only occurred in one HRQOL domain). 
 
The selected articles were evaluated for trial quality and quality of reporting on HRQOL. 
 
Trial quality was evaluated with the Jadad scale [21]. The maximum possible score was 13 
points using an11item instrument. This was considered to be good when the score was more 
than 9 points and poor when the score was equal to or less than 9 points. Items related directly 
to the control of bias using the Jadad scale are: 
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1. Was the study designed as randomised? 
2. Was the study designed as double blind? 
3. Was there a description of withdrawals and drop outs? 
Other markers not related directly to the control of bias: 
1. Were the objectives of the study defined? 
2. Were the outcome measures defined clearly? 
3. Was there a clear description of the inclusion and exclusion criteria? 
4. Was the sample size justified (for example, power calculation)? 
5. Was there a clear description of the interventions? 
6. Was there at least one control (comparison) group? 
7. Was the method used to assess adverse effects described? 
8. Were the methods of statistical analysis described? 
 
Items are scored as follows: 
-Give either a score of 1 point for each « yes » or 0 points for each « no ». There are no 
inbetween marks. 
-Give 1 additional point if, for question 1, the method to generate the sequence of 
randomisation was described and was appropriate (table of random numbers, computer 
generated, etc.) and/ or if, for question 2, the method of double blinding was described and 
was appropriate (identical placebo, active placebo, dummy, etc.). 
-Deduct 1 point if, for question 1, the method to generate the sequence of randomisation was 
described and was inappropriate (patients were allocated alternately, or according to date of 
birth, hospital number, etc.) and/or if, for question 2, the study was described as double blind 
but the method of blinding was inappropriate (for example, comparison of tablet versus 
injection with no double dummy). 
 
The criteria used to evaluate quality of reporting on HRQOL were based on those proposed by 
Efficace et al [11] (table 1) 
This 11-item checklist was developed on the basis of good practice in conducting a HRQOL 
evaluation and it was specifically aimed at evaluating the reported quality of the HRQOL 
assessment methodology in a clinical trial setting. The checklist items were devised to have a 
dichotomous answer; these can be scored as « yes » (giving a score of 1) or « no » (giving a 
score of 0), the higher the score the higher the considered robustness of the outcomes. This 
checklist addresses the basic and essential issues that a given trial should report to have 
methodologically sound outcomes. 
The original checklist also included whether the measure covered, at least, the main HRQOL 
dimensions relevant for a generic cancer population. This criterion has been built into this 
review automatically. 
Studies scoring at least seven on this checklist including three mandatory items (i.e. baseline 
compliance, missing data and psychometric properties reported) could be considered as 
probably robust‘. Hence, all studies were classified into « probably robust » (as defined 
above), limited‘(scoring higher than three but either lower than seven or not including all 
three mandatory items), and very limited‘ (all other studies, i.e. scoring three or lower on the 
checklist score). 
When an article provided explicit reference to a related paper reporting additional data, this 
was retrieved as well. When more than one paper reported HRQOL data of the same trial, 
information was pooled to be reported in the tables. 
 
Ethical aspects 
In accordance with French regulations, this study was exempted from IRB approval. 
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Table 1 Minimum Standard Checklist for Evaluating HRQOL Outcomes in Cancer Clinical 
Trials [11] 
 
HRQOL Issue Answer Description 
Conceptual 
A priori hypothesis 
stated 
Yes No N/A
* 
Assessed whether authors had a predefined 
HRQOL end point and/or stated expected 
changes because of the specific treatment. 
Rationale for instrument 
reported 
Yes No  Assessed whether authors gave a rationale for 
using a specific HRQOL measure. 
Measurement 
Psychometric properties 
reported 
Yes No  Assessed whether a previously validated 
measure was used or psychometric properties 
were reported or referenced in the article. 
Cultural validity verified Yes No N/A  Assessed whether the measure was validated 
for the specific study population. 
Adequacy of domains 
covered 
Yes No  Assessed whether the measure covered, at 
least, the main HRQOL dimensions relevant 
for a generic cancer population and/or 
according to the specific research question. 
Methodology 
Instrument 
administration reported 
Yes No  Assessed whether authors specified who 
and/or in which clinical setting the HRQOL 
instrument was administered. 
Baseline compliance 
reported 
Yes No  Assessed whether authors reported the number 
of patients providing an HRQOL assessment 
before the start of treatment. 
Timing of assessments 
documented 
Yes No  Assessed whether authors specified the 
HRQOL timing of assessment during the trial. 
Missing data 
documented 
Yes No  Assessed whether authors gave some details 
on HRQOL missing data during the trial. 
Interpretation 
Clinical significance 
addressed 
Yes No  This refers to the discussion of HRQOL data 
being clinically significant from a patient’s 
perspective and not simply statistically 
significant. 
Presentation of results in 
general 
Yes No  Assessed whether authors discussed the 
HRQOL outcomes, giving any comments 
regardless of the results (either expected or 
not). 
Abbreviation: HRQOL, health-related quality of life. 
*If a study explicitly states an exploratory HRQOL evaluation.  
 If the HRQOL measure is validated in the same population as the one of the trial. 
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RESULTS 
 
The appendix list all articles reviewed. 
 
According to the eligibility criteria, a total of 26 citations were identified that included 
HRQOL outcomes in 24 randomized clinical trials. Besides these, three other studies were 
also retrieved, but excluded from trial analyses (with the consensus of all authors). One of 
these studies met our criteria, but did not report any details about the methodology used to 
assess HRQOL and the remaining two was excluded because it was impossible to check for 
the HRQOL measure used. 
 
Demographics and trial design characteristics 
The studies were conducted across a variety of countries: 16 (66,6%) in European countries, 
two (8,3%) in the USA, two (8,3%) in Asia , one (4,2%) in Australia, one (4,2%) in Burkina 
Faso. and two (8,3%) were conducted on an international setting. 
Eight (33,3 %) of the 24 studies were industry sponsored, as identified by author affiliation 
with a company or by a statement regarding commercial funding. 
 
Half of the trials were multicenter studies. 
 
The number of patients enrolled into the trials varied considerably, ranging from 27 to 700 
patients, with a total of 3476 patients. 
 
A total of 23 trial reports (95.8%) stated that a research ethics committee had approved the 
research and reported that informed consent from patients had been requested from the 
participants. 
 
Methodological quality 
 
The methodological quality score (Jadad scale) ranged from 8 to 13, with a mean of 10.6 +/-
1.07. Only 5 articles, in which the study was described as double blind and could therefore 
score an extra 2 points, were eligible for the maximum possible score of 13, and just 2 
achieved this score. 
The methodological quality was insufficient (score ˂ 9) for only one trial (table 2).All trials 
were randomized, but three trials (12,5%) were randomized without the method of 
randomization being specified. All but one trial detailed trial inclusion and exclusion criteria. 
 
Table 2: numbers of trials according to the Jadad score [21] (n=24) 
 
Score ≤7 8 9 10 11 12 13 
No. 
trials 
0 1 2 7 12 0 2 
 
 
HRQOL assessment 
 
The 24 RCTs identified were classified according to the predefined checklist. One of these 
could be considered as very limited in terms of methodological design according to previously 
defined criteria (4%) .Twelve trials (50%) were considered limited while eleven (45,8%) 
where evaluated as being probably robust. The overall level of reporting is provided in table 
3. 
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14 distinct QOL questionnaires (5 generic, 9 specific) were used in the 24 studies analyzed. 
The most frequently used instrument (in conjunction or not with other tools) was the Short 
Form 36-item questionnaire in 13 trials, and the European Organisation for Research and 
Treatment of Cancer Quality of Life Questionnaire C30 in four trials. 
In two studies SF-36 was administered in a modified version, attempting to give a more 
comprehensive HRQOL assessment but altering the psychometric properties of the original 
tool. 
45 % (11/24) of the reports described the questionnaires, i.e. the number of dimensions and 
their contents, such as the number of items per dimension, and the minimal and maximal 
scores. Only the name of the questionnaire was given in 13 others. 
 
QOL was a primary endpoint in only six (25%) studies. QOL was a secondary endpoint in 
75% (18/24) of the analyzed reports. In two of them, trial results were published in several 
different articles, one relating the QOL findings and the other(s) the clinical outcomes. Only 
five (20,8 %) studies reported the use of power calculations for HRQOL aspects. 
 
Only ten studies (41,6%) reported a priori hypotheses and only five studies (20,8%) provided 
a rationale for selecting a HRQOL measure. 
Information about the administration of the HRQOL questionnaire was mentioned in 13 
(54,1%) reports. 
 
Three RCTs (12,5%) did not provide the absolute number or the percentage of patients who 
completed the questionnaire before commencing the trial. 
 
Methods of health-related quality of life analysis and results 
 
The response rate for quality of life end points was given in 19 of the studies, with response 
rates ranging from 14,2 % to 100%. 
Nine RCTs (37,5%) did not provide any details about HRQOL missing data during the course 
of the trial. Furthermore, in those trials where an indication of HRQOL missing data was 
provided, only one trial undertook a detailed statistical exploration of the biases due to 
missing data. The remaining studies did not investigate this issue. 
Reporting the level of missing data and the reasons why the data is missing (ie, random or 
systematic) are factors critical to understanding any possible source of bias in determining 
HRQOL significance 
 
However, all studies provided details about the timing of HRQOL assessment and 14 (58,3%) 
discussed somehow the HRQOL outcomes in the paper. 
 
All RCTs, with the exception of one, applied a statistical test for determining a HRQOL 
difference between treatment arms. 
 
Of the 23 eligible studies, 11 (47,8%) found some significant difference on HRQOL scales 
between arms. 
 
Obtaining a statistical difference in terms of HRQOL outcome does not necessarily imply a 
clinically meaningful difference from a patients' perspective (24). But only six (25%) 
discussed the related HRQOL outcomes in terms of clinical significance from a patient's 
perspective. This issue is closely related to the difficulty in interpreting the HRQOL data from 
a given measure. 
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Table 3. Level of Reporting According to the Minimum Standard Checklist for Evaluating 
HRQOL Outcomes in Cancer Clinical Trials 
 
HRQOL Issue No* % 
Conceptual 
A priori hypothesis stated 10/24 41,6 
Rationale for instrument reported 5/24 20,8 
Measurement 
Psychometric properties reported 22/24 91,6 
Cultural validity verified 22/24 91,6 
Methodology 
Instrument administration reported 13/24 54,1 
Baseline compliance reported 21/24 87,5 
Timing of assessments documented 24/24 100 
Missing data documented 15/24 62,5 
Interpretation 
Clinical significance addressed 8/24 33,3 
Presentation of results in general 23/24 95,8 
Abbreviation: HRQOL, health-related quality of life. 
*Number of articles reporting item/number of articles to which item is applicable. 
 
 
DISCUSSION 
 
Inadequate reporting of randomised controlled trials is common and hampers the appraisal of 
the validity and generalisability of results[22, 23]. To overcome such problems, the 
Consolidated Standards for reporting of Trials (CONSORT) Group developed the CONSORT 
statement [24] in 1996, which was followed by a revised version in 2001[25]. 
This can explain the high level of the mean Jadad score found in our study. 
The main objective of this article was to evaluate the methodological quality of RCTs with a 
HRQOL component in gastrointestinal surgery. 
 
Using the stated selection and eligibility criteria, we found 24 RCTs with HRQOL assessment 
which included some 3476 patients. HRQOL was a secondary end point in most trials (75%). 
 
The aim of our study was not to compare results with other medical or surgical specialities but 
to describe how digestive surgeons use HRQOL in their trials and to find how to improve. 
However, compared with other HRQOL studies in other disease sites and treatments [12-19, 
26, 27] (table 4) the overall quality of the reported trials is good, although there are a number 
of shortcomings with regard to the reporting of the HRQOL design and results. 
 
Among the studies reviewed, there is generally poor details about the rationale for selecting a 
specific measure and instrument administration. 
A justification for selecting the HRQOL measure was given in only five studies (20,8%).In 
others reviews this justification was given in 9,7 to 90% of the trials (table 4).This point has to 
be improved as well in surgery as for others specialities.  
This is regarded as important because instrument selection is critical for reliability, validity, 
and reproducible results. 
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It is also important to standardize the instructions and completion procedures of assessment 
material administered to patients, particularly in RCTs, because often many researchers and 
institutions are involved in collecting HRQOL data. Thus, standard procedures help to ensure 
adequate data quality and minimize any possible bias in data collection.( For example, will 
patients answer the questionnaire at a clinic visit, by telephone, by mail? Is it to be done by 
the investigator, his colleagues, or a research nurse?) 
Our study was in accordance with previous studies (table 4) where instrument administration 
was reported in 0 to 66,6%. 
 
A major methodological drawback was a lack of a priori hypothesis about possible HRQOL 
changes before commencing the trial. Only ten RCTs (41,6%) explicitly stated an a priori 
hypothesis thus limiting spurious HRQOL results due to multiple significance testing . This 
results was similar and even better to the majority of previous study where the a priori 
hypothesis was stated in 13 to 72,7% of the trials (table 4). 
A key consideration for future studies is the selection of a limited number of HRQOL 
indicators before commencing the trial, possibly basing this selection on previous related 
trials, or on a specific a priori research hypothesis about the impact of a given therapy. 
 
One major issue is the reporting of compliance at baseline and the documentation of missing 
data. Three RCTs (12,5 %) did not provide the absolute number or the percentage of patients 
who completed the questionnaire before commencing the trial and 9 (37,5%) did not provide 
any details about HRQOL missing data during the course of the trial. 
This result was similar to previous studies where missing data were documented in only 48,4 
to 74,8% (table 4). 
Although the majority of trials started with reasonable sample sizes, many were plagued with 
problems of patient drop-out. Such attrition often limits the general robustness of the results 
and reduces confidence in the HRQOL conclusions. Data are generally not missing at random 
and therefore bias can be introduced [17, 28-30]. The benefit of a intervention may be 
overestimated by comparison of group means as only individuals who remain well enough to 
fill in questionnaires provide data. The unreported details of missing data is a frequent 
problem in studies where HRQOL is measured [31] and previous works already proposed 
procedures to address this issue [32, 33]. More attention to improving compliance and 
reporting in future studies would be valuable. 
 
Of the 23 eligible studies, 11 (47,8%) found some significant difference on HRQOL scales 
between arms. This would indicate that the HRQOL measures are valuable in providing 
additional data. 
However, although HRQOL differences were observed, it is necessary to remember that, 
whereas many subscales are often used and compared over treatments and time, not all 
subscales will show a significant difference. 
This underlines the need to declare in advance the HRQOL hypotheses and the importance of 
careful interpretation of multiple repeated statistical analyses. 
 
A further trap in analysis of HRQOL data is the difference between statistical and clinical 
significance in changes of scores. It is acknowledged that, although analysis of large samples 
may reveal small changes that seem to be statistically significant, these changes may not be 
clinically meaningful to the patient and are, therefore, of limited value to the improvement of 
patient care. 
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An effort to determine if such small numerical differences have a clinical meaning from a 
patient's perspective has been highlighted as an important aspect for determining the impact 
of a given treatment [28, 34]. 
 
Unfortunately, only six of these studies (26%) examined the clinical significance of apparent 
differences. It is highly desirable that future studies will routinely include the concept of 
clinical significance to help evaluate the value of HRQOL results. 
 
Furthermore, in several RCTs, the HRQL results were not formally presented, but the main 
results were described in the text. 
It is possible that this occurred because most trials used HRQOL as a secondary end point. In 
such trials, it is frequently observed that limited space is given to HRQOL data, with priority 
given to the primary clinical end point. 
Two authors have overcome this difficulty by separately reporting clinical and HRQL trial 
outcomes. 
This is an opportunity for adequate explanation and presentation of what may often be 
complex results. 
However the disadvantage of splitting the HRQL data from the main trial paper is that 
surgeons are unlikely to read the HRQL paper once the main clinical message of a particularly 
trial has been published. If this occurs, then during the process of clinical decision making the 
HRQL impacts of treatment may be overlooked [19]. It is therefore recommended that clinical 
and HRQL outcomes are published together so that clinical decision making is based upon 
relevant patient-centered endpoints. 
 
Whilst we identified the above reported methodological limitations, it was impressive that 
nearly all the studies used HRQOL valid measures and provided details on the HRQOL 
timing of assessment during the trial. 
 
There were eleven trials (45,8%) with robust HRQL design, and statistically significant 
differences in HRQL were reported in six of these trials.Only one trial « very limited » (4%) 
could be invalidated by its lack of rigor in presenting HRQOL data. 
Pertinently, the strict methodological approach to the assessment of the patient-based QOL 
criteria in the evaluation of therapeutic strategies can help, patients and their doctors, in 
medical decision making. 
The Efficace’s checklist can be considered as a minimum standard ; however, HRQOL design 
also greatly depends on the context and the specific research question of the trial; hence good 
reports may have different emphases and some issues might have different relevance 
according to the specific study questions[11]. 
If HRQL is considered to be a relevant outcome in a clinical trial and if HRQL is assessed 
robustly, then it will always contribute to clinical decision making regardless of the direction 
of the outcomes [11, 26]. Only if HRQL assessments are flawed (underpowered study, too 
many missing data items, invalid questionnaires) may they not contribute to clinical decision 
making.  
 
 Our study showed some limitations. We selected randomised controlled trials (RCTs) from 
12 journals. This restrictive choice was led by the recognised quality of the four medical 
journals selected (leading journals that publish research reports in all fields and have a broad 
readership) and because the eight surgical journals comprised a good sample of surgery 
around the world. The purpose of this choice was to create a homogeneous group of 
publications and conditions that allowed standardised analysis. This arbitrary choice may 
 12 
have introduced a bias causing overestimation of the quality of the RCTs analysed. In 
addition, authors of original articles were not pursued for additional data or for clarification of 
points that were unclear about trial methodology. 
We recognise also that our review is limited by its restriction to RCTs, but the checklist 
developed  by Efficace and al [11]was originally devised only for this type of design. 
It could be interesting to develop an applicable and useful checklist for not randomized 
studies. 
Despite these potential limitations, this paper suggests that surgeons are interested in HRQL 
outcomes and that HRQOL assessment in RCT settings has the potential to provide invaluable 
data for developing new treatments in gastrointestinal surgery. 
 
 
CONCLUSION 
 
Despite the emphasis on quality of life outcomes, there are still deficiencies in the execution 
of these studies. 
In attempt to improve in the future the use of QOL as an endpoint in RCTs, researchers 
should include prior statement of hypotheses, better reporting, improved compliance, detailed 
methods of analysis, and reporting of missing data. 
Such improvements will enhance the reliability of future HRQOL investigations with the 
ultimate aim of giving a comprehensive picture of a given treatment and also facilitate clinical 
decision-making.
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Table 4 : Results of previous review on RCTs reporting HRQOL evaluation by the Efficace’s checklist 
  Conceptual 
 
Measurement Methodology Interpretation 
N A priori 
hypothesis 
stated 
Rationale 
for 
instrument 
reported 
Psychometric 
properties 
reported 
Cultural 
validity 
verified 
Instrument 
administration 
reported 
Baseline 
compliance 
reported  
Timing of 
assessments 
documented 
Missing data 
documented 
Clinical 
significance 
addressed 
Presentation 
of results in 
general 
Our study 
 
Gastrointestinal 
surgery 
(2006-2007) 
24 41,6 % 20,8% 91,6% 91,6% 54,1% 87,5% 100% 62,5% 33,3% 95,8% 
Efficace[11] Prostate cancer 
(1980-2001) 
24 13% 29% 87% 81% 25% 46% 96% 54% 12% 67% 
Efficace [12] Brain cancer 
(1980-2001) 
5 20% 80% NA 50% 0% 100% 100% 60% 40% 80% 
Bottomley[14] Non-small-cell-
lung cancer 
(1980-2002) 
29 31% 34,5% NA 13/13 34,5% 13,8% 29/29 62% 20,7% 58,6% 
Efficace[17] Colorectal 
cancer 
(1980-2003) 
31 25,8% 9,7% 100% 94,7% 9,7% 61,3% 100% 48,4% 12,9% 
 
93,5% 
Efficace[18] Leukaemia 
(1980-2007) 
9 22,2% 55,5% 100% 100% 66,6% 83,3% 100% 66,6% 44,4% 100% 
Gujral [19] Surgery for 
colorectal 
cancer 
(1980-2006) 
8 50% 87,5% NA NA 25% 20% 8/8 50% 66,6% 62,5% 
Blazeby[26] Surgical 
oncology 
(1985-2005) 
33 72,7 % 
 
90,9 % NA NA 63,6% 45,4% 90,9% 54,5% NA NA 
Efficace[27] Cancer clinical 
trials 
(1990-2004) 
159 28,9% 47,8% 94,3% 96,6% 30,8% 75,5% 99,4% 74,8% 24,5% 93,1% 
NA= not available
 14 
REFERENCES 
1. Kluivers KB, Riphagen I, Vierhout ME, Brolmann HA, de Vet HC: Systematic review on 
recovery specific quality-of-life instruments. Surgery 2008;143:206-215. 
2. Schumacher M, Olschewski M, Schulgen G: Assessment of quality of life in clinical trials. Stat 
Med 1991;10:1915-1930. 
3. Leplege A, Hunt S: The problem of quality of life in medicine. Jama 1997;278:47-50. 
4. Kong SX, Gandhi SK: Methodologic assessments of quality of life measures in clinical trials. 
Ann Pharmacother 1997;31:830-836. 
5. Velikova G, Stark D, Selby P: Quality of life instruments in oncology. Eur J Cancer 
1999;35:1571-1580. 
6. Aaronson NK, Muller M, Cohen PD, Essink-Bot ML, Fekkes M, Sanderman R, Sprangers MA, te 
Velde A, Verrips E: Translation, validation, and norming of the Dutch language version of the SF-36 
Health Survey in community and chronic disease populations. J Clin Epidemiol 1998;51:1055-1068. 
7. Eypasch E, Williams JI, Wood-Dauphinee S, Ure BM, Schmulling C, Neugebauer E, Troidl H: 
Gastrointestinal Quality of Life Index: development, validation and application of a new instrument. 
Br J Surg 1995;82:216-222. 
8. Guyatt GH, Bombardier C, Tugwell PX: Measuring disease-specific quality of life in clinical 
trials. Cmaj 1986;134:889-895. 
9. Staquet M, Berzon R, Osoba D, Machin D: Guidelines for reporting results of quality of life 
assessments in clinical trials. Qual Life Res 1996;5:496-502. 
10. Avery K, Blazeby JM: Quality of life assessment in surgical oncology trials. World J Surg 
2006;30:1163-1172. 
11. Efficace F, Bottomley A, Osoba D, Gotay C, Flechtner H, D'Haese S, Zurlo A: Beyond the 
development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL 
outcomes in cancer clinical trials--does HRQOL evaluation in prostate cancer research inform clinical 
decision making? J Clin Oncol 2003;21:3502-3511. 
12. Efficace F, Bottomley A: Health related quality of life assessment methodology and reported 
outcomes in randomised controlled trials of primary brain cancer patients. Eur J Cancer 
2002;38:1824-1831. 
13. Efficace F, Bottomley A, van Andel G: Health related quality of life in prostate carcinoma 
patients: a systematic review of randomized controlled trials. Cancer 2003;97:377-388. 
14. Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH: Health-related quality of life 
in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J Clin Oncol 
2003;21:2982-2992. 
15. Bottomley A, Therasse P: Quality of life in patients undergoing systemic therapy for advanced 
breast cancer. Lancet Oncol 2002;3:620-628. 
16. Goodwin PJ, Black JT, Bordeleau LJ, Ganz PA: Health-related quality-of-life measurement in 
randomized clinical trials in breast cancer--taking stock. J Natl Cancer Inst 2003;95:263-281. 
17. Efficace F, Bottomley A, Vanvoorden V, Blazeby JM: Methodological issues in assessing 
health-related quality of life of colorectal cancer patients in randomised controlled trials. Eur J 
Cancer 2004;40:187-197. 
18. Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B: Health-related quality of 
life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic 
review to evaluate the added value in supporting clinical decision making. Eur J Cancer 
2008;44:1497-1506. 
19. Gujral S, Avery KN, Blazeby JM: Quality of life after surgery for colorectal cancer: clinical 
implications of results from randomised trials. Support Care Cancer 2008;16:127-132. 
20. Moher D, Jones A, Lepage L: Use of the CONSORT statement and quality of reports of 
randomized trials: a comparative before-and-after evaluation. Jama 2001;285:1992-1995. 
21. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, McQuay HJ: Assessing 
the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 
1996;17:1-12. 
 15 
22. Moher D, Jadad AR, Tugwell P: Assessing the quality of randomized controlled trials. Current 
issues and future directions. Int J Technol Assess Health Care 1996;12:195-208. 
23. Juni P, Altman DG, Egger M: Systematic reviews in health care: Assessing the quality of 
controlled clinical trials. Bmj 2001;323:42-46. 
24. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I, Pitkin R, Rennie D, Schulz KF, Simel D, 
Stroup DF: Improving the quality of reporting of randomized controlled trials. The CONSORT 
statement. Jama 1996;276:637-639. 
25. Moher D, Schulz KF, Altman DG: The CONSORT statement: revised recommendations for 
improving the quality of reports of parallel-group randomised trials. Lancet 2001;357:1191-1194. 
26. Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J: Health-related quality of 
life measurement in randomized clinical trials in surgical oncology. J Clin Oncol 2006;24:3178-3186. 
27. Efficace F, Osoba D, Gotay C, Sprangers M, Coens C, Bottomley A: Has the quality of health-
related quality of life reporting in cancer clinical trials improved over time? Towards bridging the gap 
with clinical decision making. Ann Oncol 2007;18:775-781. 
28. Osoba D, Rodrigues G, Myles J, Zee B, Pater J: Interpreting the significance of changes in 
health-related quality-of-life scores. J Clin Oncol 1998;16:139-144. 
29. Sprangers MA, Moinpour CM, Moynihan TJ, Patrick DL, Revicki DA: Assessing meaningful 
change in quality of life over time: a users' guide for clinicians. Mayo Clin Proc 2002;77:561-571. 
30. Troxel AB, Fairclough DL, Curran D, Hahn EA: Statistical analysis of quality of life with missing 
data in cancer clinical trials. Stat Med 1998;17:653-666. 
31. Bernhard J, Cella DF, Coates AS, Fallowfield L, Ganz PA, Moinpour CM, Mosconi P, Osoba D, 
Simes J, Hurny C: Missing quality of life data in cancer clinical trials: serious problems and challenges. 
Stat Med 1998;17:517-532. 
32. Conroy T, Bleiberg H, Glimelius B: Quality of life in patients with advanced colorectal cancer: 
what has been learnt? Eur J Cancer 2003;39:287-294. 
33. Young T, de Haes H, Curran D: Guidelines for Assessing Quality of Life in EORTC Clinical Trials. 
The EORTC Quality of Life Group & EORTC Quality of Life Unit, version 2.0. , EORTC Publications, 
Brussels (2002). 
34. Osoba D: A taxonomy of the uses of health-related quality-of-life instruments in cancer care 
and the clinical meaningfulness of the results. Med Care 2002;40:III31-38. 
 
 
